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ABSTRACT
Objective: To explore dementia management from a primary care physician perspective.
Design: One-page seven-item multiple choice questionnaire; free text space for every item; final
narrative question of a dementia case story. Inductive explorative grounded theory analysis.
Derived results in cluster analyses. Appropriateness of dementia drugs assessed by tertiary care
specialist.
Setting: Twenty-five European General Practice Research Network member countries.
Subjects: Four hundred and forty-five key informant primary care physician respondents of
which 106 presented 155 case stories.
Main outcome measures: Processes and typologies of dementia management. Proportion of
case stories with drug treatment and treatment according to guidelines.
Results: Unburdening dementia – a basic social process – explained physicians’ dementia man-
agement according to a grounded theory analysis using both qualitative and quantitative data.
Unburdening starts with Recognizing the dementia burden by Burden Identification and Burden
Assessment followed by Burden Relief. Drugs to relieve the dementia burden were reported for
130 of 155 patients; acetylcholinesterase inhibitors or memantine treatment in 89 of 155
patients – 60% appropriate according to guidelines and 40% outside of guidelines. More Central
and Northern primary care physicians were allowed to prescribe, and more were engaged in
dementia management than Eastern and Mediterranean physicians according to cluster analyses.
Physicians typically identified and assessed the dementia burden and then tried to relieve it,
commonly by drug prescriptions, but also by community health and home help services, men-
tioned in more than half of the case stories.
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Conclusions: Primary care physician dementia management was explained by an Unburdening
process with the goal to relieve the dementia burden, mainly by drugs often prescribed outside
of guideline indications.
Implications: Unique data about dementia management by European primary care physicians
to inform appropriate stakeholders.
KEY POINTS
Dementia as a syndrome of cognitive and functional decline and behavioural and psychological
symptoms causes a tremendous burden on patients, their families, and society.
 We found that a basic social process of Unburdening dementia explained dementia manage-
ment according to case stories and survey comments from primary care physicians in 25
countries.
 First, Burden Recognition by Identification and Assessment and then Burden Relief – often by
drugs.
 Prescribing physicians repeatedly broadened guideline indications for dementia drugs. The
more physicians were allowed to prescribe dementia drugs, the more they were responsible
for the dementia work-up.
Our study provides unique data about dementia management in European primary care for the
benefit of national and international stakeholders.
Introduction
Dementia arises together with the accumulation of
harms and disease burdens over the life course, and
clusters with other endemic conditions exacerbating
each other synergistically [1,2]. Multimorbidity and car-
diovascular comorbidity show prevalences of 65–98%
for those more than 65 years of age [3] with accompa-
nying polypharmacy and potentially inappropiate
medications adding to the burdens [4]. Dementia can
be seen as a triad of impairments and burdens: cogni-
tive, emotional, and physical [2] in a ‘frail brain’ [5].
Dementia eventually results in disabled instrumental
and basic activities of daily life, neuropsychiatric
issues, personality changes, social impairment and
stigma [6]. These disease burdens are often long last-
ing and indeed affect family caregivers who often
develop depression and physical illnesses while caring
for their loved ones [7]. A systematic review domi-
nated by qualitative studies of dementia management
in primary care showed lack of support for patients,
caregivers and primary care physicians and an attitude
of ‘therapeutic nihilism’ [8]. There was also limited
access to and knowledge about community services
and resources and absence of interdisciplinary teams
to enhance management [8]. Other main themes from
the qualitative studies were ‘time constraints, financial
constraints, stigma, diagnostic uncertainty, and disclos-
ing the diagnosis’ [8]. With this gloomy review as
background, we wanted to explore dementia manage-
ment using an inductive approach from classic
grounded theory where the basic research question is
‘what is going on?’ We wanted to know how primary
care physicians in different countries treat their
patients suffering from dementia, and to generate an
explanatory theory of dementia management in pri-
mary care.
Methods
Study design
For this survey study directed to primary care physi-
cians in 25 countries of the European General Practice
Research Network (EGPRN), we developed a seven-
item multiple choice questionnaire (MCQ). The design
of the survey has been presented elsewhere [9,10]. At
the end of every MCQ, optional free text comments
could be added [10]. In the eighth and last survey
item, we invited respondents to contribute anony-
mised case stories of dementia from their own
practice.
We applied an analytic classic grounded theory
approach characterised by inductive reasoning with
no a priori hypotheses allowing both qualitative and
quantitative data analysis [11–13].
Setting
In the 25 countries, national key informants were iden-
tified and contacted face to face by author FP during
meetings of the EGPRN and WONCA Europe conferen-
ces in 2013–2015. National key informants organised
translation of the survey into their own languages and
back translation to English. They also selected further
key informants from different geographical and socio-
economic regions within their country by convenience
or snowball sampling.
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Participants and data
445 key informant primary care physicians from 25
countries, of which 106 physicians from 23 countries
presented 155 case stories.
Data coded for this study:
i. Secondary analysis of MCQ data provided by
445 key informants and 8,000 words of free text
data from the same survey [9,10].
ii. Data from 106 key informants who provided 155
case stories consisting of 40,000 words.
Grounded theory analysis
Classic grounded theory is the world’s most cited
behavioral research method with 124,055 Google
Scholar citations (15 July 2020) [11]. In classic
grounded theory, hypotheses are inductively gener-
ated to explain how participants resolve their main
concern abstract of time, place and people [11,13,14].
Classic grounded theory differs from other methods
using only qualitative data by emphasising explana-
tory concepts rather than descriptions.
Theoretical memos, in the shapes of text, diagrams,
and figures, were written, typed, or drawn to create a
200-page memo bank from which this paper was writ-
ten. ‘Memos are the theorizing write-up of ideas about
substantive codes and their theoretically coded rela-
tionships as they emerge during coding, collecting
and analysing data’ [14]. These memos were analysed
based on grounded theory quality principles of fit,
relevance, workability and modifiability [14,16]. Then
followed selective coding where the core concept
guided the analysis during theoretical memoing. We
coded case stories and survey text comments asking
for each incident in the data ‘What is the participants’
main concern and how is it being resolved?’ and
‘What are the participants doing to resolve their main
concern’ and ‘What is this a study about?’. Answers to
these coding questions yielded several hundred indi-
cators of preliminary dementia discovery, diagnosis,
work up and treatment. Theoretical memos included
codes related to care and caregivers – spouse, chil-
dren, institutional and non-institutional care etc. We
further analysed survey free text including descriptions
of formal and informal rules of dementia work up and
diagnostic and treatment structures of the jurisdiction
in which the case story took place [9].
The core concept was theoretically coded using a
basic social process [11,14–16] to explain the ongoing
resolution of the main concern in the case stories.
We also ran numerous statistical analyses based on
both grounded theory codes and results of MCQ ques-
tions. These analyses were included in memos to
deductively fit the emerging concepts by applying the
‘constant comparative method’ of grounded theory
and indeed using its dictum ‘all is data’ [14,16].
The grounded theory analysis was mainly done by
the first and last author in collaboration and analytic
consensus was reached during the write-up process
lasting several years and ending with the submission
of this manuscript. Good grounded theories should
indeed be modifiable when new data enters such as
relevant critique from reviewers [14,16].
Dementia analysis
Proxies for treatment appropriateness were aligned
with the guidelines for dementia drug therapy and
established by a tertiary care physician researcher
expert on neurocognitive disorders (author SP) [17,18].
SP also assessed the specific dementia type based on
the information given in the case stories in accordance
with the DSM-5 [19].
Statistical analysis
IBM SPSS Statistics for Windows, Version 22.0. (IBM,
Armonk, NY USA, 2013) was used for descriptive and
exploratory statistical analyses. Cluster analysis is an
exploratory method used to identify structures within
the data such as homogenous groups of cases if
grouping and differences between dependent and
independent variables is previously unknown [10,20].
We did two-step cluster analyses with variables emerg-
ing from memos. Overall goodness-of-fit of clusters
had silhouette coefficients with measures of less than
0.2 classified as poor, between 0.2 and 0.5 fair, and
more than 0.5 as a good solution quality. Fair or
higher was considered acceptable clustering with a
cut-off score at 0.3 [20]. More advanced statistical
methods such as Directed Acyclical Graphs were
applied to the data in another version of this study
available online [10].
In summary, this study involved a mix of data and
methods emphasising an inductive approach of classic
grounded theory with the goal of exploring and gen-
erating a hypothesis of what was going on in the field
of primary care physician dementia management.
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Results
A multitude of burdens was the main concern sur-
rounding the care of patients with dementia and their
caregivers. Patients and caregivers were overwhelmed
not only by the burden of dementia but often by mul-
timorbidity – present in 74% of the case stories – and
by behavioural and psychological symptoms of
dementia.
The core concept, Unburdening dementia, was
deduced as a label explaining the resolution of the
main concern.
Unburdening dementia is seen as a basic social pro-
cess starting with Identifying the burden, mostly done
by family members of the patient, then Assessing the
burden by cognitive tests, especially the Mini Mental
State Examination (MMSE), the most used cognitive
psychometric test internationally [21]. The dementia
burden is then Recognised by formal caregivers and
eventually pursued by Burden Relief, often by prescrip-
tion drugs in 130 of 155 (84%) of the cases but also
by community health and home help services, men-
tioned in more than half of the case stories. The basic
social process of Unburdening dementia is presented
in Table 1 with sub-categories and different
properties.
Unburdening explains what many physicians – both
primary care physicians and secondary care specialists
– were doing to help patients and their families.
Unburdening often resulted in Burden Relief consisting
of drug prescriptions – the most available therapeutic
tool. Acetylcholinesterase inhibitors or memantine
treatment was reported in 89 of 155 patients (57%):
60% of the prescriptions were appropriate according
to guidelines and 40% prescribed outside of guide-
lines. Antidepressants were mentioned in 27% of the
patients, and to a lesser degree other drugs such as
antipsychotics. Only 22 out of 155 case stories did not
mention any drug to relieve the dementia burden.
More than two-thirds of patients in our study that
were prescribed acetylcholinesterase inhibitors and/or
memantine had too many exclusion criteria to be
accepted into dementia drug trials [10].
In five out of 25 countries, primary care physicians
were entitled to officially prescribe reimbursable
dementia drugs. In many other countries, primary care
physicians could diagnose dementia unofficially and
prescribe specific dementia drugs to patients that
would not be reimbursed by their health insur-
ance [9,10].
The participating countries were split into types
according to the ability of primary care physicians to
prescribe a dementia drug which could subsequently
be reimbursed by the health insurance system:
‘permissive’ ¼ primary care physicians always able to
prescribe, ‘partially permissive’ ¼ need for first pre-
scription by secondary care specialist, and ‘non-per-
missive’ ¼ mandatory secondary care prescribing and
follow-up. Some primary care physicians from ‘non-
permissive’ countries prescribed dementia drugs to
their patients despite the restrictions for the purpose
of mercy and equity as an unburdening action.
The MCQ analysis showed that the more primary
care physicians were officially allowed to prescribe
dementia drugs, the more they felt responsible for the
diagnostic work-up. But they also then increasingly
seemed to engage multiprofessional community
health and home help services in unburdening tasks,
thus providing psychosocial support.
Demographics, dementia prevalence, grades of
dementia drug prescribing permissiveness in the par-
ticipating countries and share of dementia drugs pre-
scribed in the case stories per region are shown in
Table 2.
Statistical analytical procedures also showed the
relevance of Unburdening. Thus, statistical data were
used in memos to test the basic social process core
variable. This means that the statistics supported
Table 1. The basic social process of Unburdening Dementia.
Unburdening Dementia - a two-step Basic Social Process
BASIC SOCIAL PROCESS STAGE: Recognising burden after burden identification and
assessment.
Burden Relief
APPLIED TO DEMENTIA CARE : Identifying cognitive and mental burden by family caregiver.
Assessing burden by psychometric tools and then
Recognising burden by formal caregiver.
Cognitive, mental and social Burden Relief
CASE STORY ILLUSTRATION: i. Consultation together: spouse/child report
memory loss.
ii. Physician notices lack of collaboration during
consultation.
iii. Assessment with Mini Mental State Examination.
iv. Physician diagnoses the patient with dementia.
Burden Relief by community health services,
home help services and drugs
The table illustrates the basic social process of Unburdening Dementia that emerged to explain the action in the data provided by primary care physi-
cians across EGPRN countries. Basic social processes are grounded theory core variables that are ‘processural’ meaning that they have two or more clear
emergent stages [13,14]. Descriptive incidents of community health and home help services (such as nursing home care and dementia services) appeared
in more than half of the case stories as indicators of a property of Burden Relief.
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theory generation by making it less dependent on
qualitative data only, due to the large amount of data
readily coded quantitatively. After basic descriptive
statistics, we employed the analytic procedures below
during the selective coding phase.
(a) Cluster analyses
A two-step cluster analysis divided 151 case stories
into two groups (four cases had missing data). Group
1 had 76 stories and group 2 had 75 stories.
‘Permissiveness to prescribe dementia drugs’ and
‘country’ predicted group affiliation (Figure 1).
Group 1 had high involvement of primary care
physicians in the dementia work up and treatment.
Patients were from Belgium, Denmark, Finland, France,
Germany, Ireland, the Netherlands, Norway, Sweden,
and Switzerland.
Group 2 had low involvement of primary care
physicians in the dementia work up and treatment.
Patients were from Austria, Bulgaria, Croatia, Greece,
Hungary, Israel, Italy, Malta, Poland, Romania, Slovenia,
Spain, and Turkey.
The different types of dementia (neurocognitive dis-
orders) as assessed by a tertiary care physician (author
SP) are shown in Table 3. Alzheimer’s disease was the
most common dementia subtype followed by vascular
dementia. In a third of the patients, no subtype could
be specified due to lack of diagnostic information,
which resulted in the unspecified diagnoses of mild or
major neurocognitive disorders.
(b) Cross-sectional associations by chi-square
testing
There was a significant positive association between
permissiveness to prescribe dementia drugs and pri-
mary care physicians’ diagnosis of dementia. MMSE
testing was reported in 128 out of 155 cases (83%)
and was significantly associated with permissiveness
to prescribe dementia drugs but not with effective
prescription of dementia drugs. We found no signifi-
cant association between permissiveness to prescribe
dementia drugs and the mentioning of dementia
drugs or appropriateness of treatment. Neither did we
find any significant association between appropriate-
ness of treatment and early specialist involvement or
referral. Statistical measures of the testing above are
available online together with results of more
Table 2. Demographics, dementia prevalence, grades of dementia drug prescribing permissiveness in the participating countries
and share of dementia drugs prescribed in the case stories per region.
Country
Population
million people
Population 65
years old or
over (%)
Dementia
prevalence (%)
Primary care
physician allowed
to prescribe
dementia drugs?
Number of case
stories (% of total)
Proportion of
typical dementia
drug treatment per
case per region
Denmark 5.8 18.2 1.5 PARTIAL 3 (2)
Finland 5.5 19.4 1.7 NO 4 (3)
Norway 5.2 15.9 1.6 YES 6 (4)
Sweden 9.7 19.4 1.8 YES 8 (5)
North Countries, total 21 57%
Austria 8.6 18.3 1.7 NO 3 (2)
Belgium 11.3 17.8 1.8 PARTIAL 2 (1)
France 66.4 18.0 1.8 PARTIAL 5 (3)
Germany 81.2 20.8 1.9 YES 5 (3)
Ireland 4.6 12.6 1.1 YES 35 (23)
Switzerland 8.2 17.6 1.7 YES 5 (3)
The Netherlands 16.9 17.3 1.5 PARTIAL 5 (3)
West Countries, total 60 67%
Bulgaria 7.2 19.6 1.5 NO 5 (3)
Croatia 4.2 18.4 1.5 NO 3 (2)
Hungary 9.8 17.5 1.5 NO 3 (2)
Poland 38.0 14.9 1.3 NO 20 (13)
Romania 19.9 16.5 1.3 NO 10 (6)
Slovenia 2.1 17.5 1.6 PARTIAL 4 (3)
East Countries, total 45 40%
Greece 10.8 20.5 1.8 NO 4 (3)
Israel 8.5 10.3 1.1 NO 7 (5)
Italy 60.6 21.4 2.1 NO 8 (5)
Malta 0.4 17.9 1.3 NO 1 (1)
Spain 46.4 18.1 1.8 NO 6 (4)
Turkey 77.7 7.7 0.4 NO 3 (2)
Mediterranean Countries, total 29 66%
Total 155 57%
Legend: Demography, dementia prevalence, prescription rules for primary care physicians, dementia cases stories and proportion of typical dementia
drug treatment from 25 countries in the EGPRN. Data on dementia prevalence by Prince et al. 2013 and on dementia drug prescribing rules by the
Alzheimer Europe Association, 2012.
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advanced statistical methods applied to the data in a
previous version of this study [10].
Discussion
Unburdening dementia emerged as an explanation of
what physicians from 25 countries did to help patients
with dementia and their caregivers after analysing
both qualitative and quantitative data. Unburdening
dementia is, according to grounded theory taxonomy,
a core variable and was coded as a basic social pro-
cess [14–16] starting with Recognising the burden by
Burden Identification and Assessment followed by
Burden Relief. As a core variable, Unburdening is
Figure 1. Importance of predictors of primary care physician involvement in dementia work-up and treatment. Degree of
involvement is dichotomised into two groups by a two-step cluster analysis. Cluster analysis is an exploratory method to identify
structures within the data such as homogenous groups of cases if grouping is not previously known. ‘Exploratory’ means that it
makes no distinction between dependent and independent variables. We used the SPSS Version 22 two-step cluster analysis. The
most important predicting variables to allocate the informants in the two groups were ‘permissiveness to prescribe dementia drugs’
(Predictor importance PI ¼ 1) and ‘country’ (PI ¼ 0.61). All the other variables had a PI of < 0.02. Permissiveness: official permissive-
ness to prescribe typical dementia drug reimbursed by the local health care system. Country: country of the case and his/her primary
care physician. Appropriate treatment: appropriate treatment according to the dementia guidelines and the label indication. Age:
age of the case in years. Gender: gender of the case. MMSE: mini mental state examination. Number of words in case: word count in
the case description.
Table 3. Dementia drug treatment stratified by diagnostic group.
Dementia Drug
Total number of patientsDiagnosis
No regular
dementia drug
Regular dementia drug (acetylcholinesterase
inhibitors/memantine)
No diagnostic information available 4 0 4
Alzheimer’s Disease/Major Neurocognitive Disorder () 9 31 40
Vascular Dementia /Major Neurocognitive Disorder (†) 12 4 16
Major Neurocognitive Disorder unspecified (b) 19 31 50
Normal Pressure Hydrocephalus 1 0 1
Mild Neurocognitive Disorder unspecified 5 0 5
Major Neurocognitive Disorders, mixed aetiologies 10 22 32
Fronto-Temporal Dementia (b) 3 1 4
Dementia of Lewy Body 1 0 1
Alzheimer’s Disease/ Mild Neurocognitive Disorders 2 0 2
Total 66 89 155
Legend: Memantine and acetylcholinesterase inhibitors were considered appropriately used if they were prescribed to patients with Alzheimer’s disease
(AD), mixed dementia (if AD was considered one of the components), dementia with Lewy bodies or Parkinson’s disease dementia. The indication for
the treatment was considered correct regardless of dementia stage (i.e. memantine was not restricted to moderate to severe AD and acetylcholinesterase
inhibitors was not restricted to mild to moderate AD) [21].
() ¼ appropriate prescription of acetylcholinesterase inhibitors/memantine.
(b) ¼ questionable prescription of acetylcholinesterase inhibitors/memantine.
(†) ¼ inappropriate prescription of acetylcholinesterase inhibitors/memantine.
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suggested as a cohesive explanation for the resolution
of a main concern – the comprehensive burden of
dementia – and as such a tentative explanatory theory
of dementia management in primary care.
We analysed case histories and survey responses
from primary care physicians in 25 countries and
found that only in 14% of 155 case stories was there
no mention of any drug to relieve dementia problems.
In more than half of the case stories, acetylcholinester-
ase inhibitors and/or memantine were mentioned as
being prescribed and in one quarter of case stories,
guideline indications of dementia drug treatment
were broadened [17,18]. The physicians also used
other drugs to unburden dementia such as
antidepressants.
Free text data and MCQ responses, confirmed by a
two-step cluster analysis, showed that the more the
primary care physicians were officially allowed to pre-
scribe dementia drugs the more they were responsible
for the dementia work-up [9,10] also engaging com-
munity health and home help services in unburdening
tasks. Pro-active dementia management by primary
care physicians was related to geographical region
with Central and Northern European physicians show-
ing high permissiveness to prescribe dementia drugs
in comparison with a low prescribing permissiveness
in Eastern European and Mediterranean countries. This
finding of regional differences within Europe con-
firmed a pattern seen previously [9,10].
‘Label indications’ of drugs are often limited and
narrow [6,18]. Yet, both primary and secondary care
physicians do not always apply a strict indication per-
spective. They have a patient with multiple severe
conditions in front of them and try to do their best to
help that patient [22]. The most common tool that
many physicians use to help their patients is the pre-
scription of drugs. Physicians inevitably tend to
broaden the indications for drugs which could be
beneficial even though the patient does not fulfill the
eligibility criteria for prescription [23]. We call this pat-
tern of physician behaviour Unburdening by drugs.
A majority of patients in our study that were pre-
scribed specific dementia drugs would not have been
accepted in dementia drug trials that sit as the base
for the alleged evidence of their effects [10]. Patients
in our study were indeed on average 80 years old and
had significant co-morbidity. This suggests a discrep-
ancy between real world primary care dementia
patients and patients from acetylcholinesterase inhibi-
tor trials where the efficacy of these drugs was deter-
mined. Patients in our study were thus old, with high
co-morbidity and a late diagnosis often due to the
difficulty of establishing a diagnosis. The discrepancy
further applies to patients being included in disease
modifying anti-amyloid trials aimed at relieving the
dementia burden at the micro level [24,25]. Our study
suggests that since many patients with dementia in
primary care are treated outside of the traditional pro-
tocols for the drug trials that were designed to prove
their effects, it would seem logical to expand the drug
trial populations to include typical primary care
patients.
Limitations
Day care rehabilitation, respite care and caregiver sup-
port [26] etc. are much less mentioned as Burden
Relief procedures in our study as compared to pre-
scribing dementia drugs of sometimes marginal thera-
peutic effect [17,18]. Why Unburdening by drugs
emerged as the most common Burden Relief strategy
used by the primary care physicians could perhaps be
explained by a ‘prescription reflex’ response against
therapeutic nihilism [27]. The big picture of the case
stories analysed for this study resembles data from a
systematic review of barriers to dementia manage-
ment which showed limited access to and knowledge
about community services and absence of interdiscip-
linary teams as well as attitudes of therapeutic nihilism
[8]. The respondents in our study could have been
biased for the eighth case story survey item by ques-
tions 3 and 4 in the MCQ survey that asked about
drug treatment.
Our recruitment and sampling of key respondents
was strategic, which limits generalizability. Also, the
proportion of case story data from Ireland and Poland
was higher than from other countries and differences
within countries are not considered since the survey
was anonymous. Yet, we used the same data collec-
tion approach for all countries. Moreover, with hun-
dreds of pages of case story text and free text
responses from several hundred primary care physi-
cians we reached conceptual saturation according to
grounded theory principles of fit, relevance, workabil-
ity and modifiability [14,16]. These are qualities that in
traditional qualitative data analysis often are labeled
trustworthiness and generalizability. Hence, we sug-
gest that Unburdening as a basic social process is
enough abstract of time, place and people to be con-
sidered useful for a general understanding of practice
habits of primary care physicians.
Our inductive method was based on classic
grounded theory that mostly analyses qualitative data.
Yet, we used quantitative measures too, rare for classic
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grounded theory but they fit our data [11–13]. Thus,
Unburdening dementia emerged as a relevant basic
social process. Since our data was based on what
informants chose to report the results should, as in all
classic grounded theory research, not be seen as facts
but as tentative hypotheses. This is a limitation in
deductive research but fits the tenets of the inductive
property of the classic grounded theory method.
In many case stories, specification of the type of
dementia was not given by the respondents and this
is similar to other studies in primary care where the
subtype of dementia was not considered [28]. Hence,
a tertiary care physician researcher carefully examined
all case stories and tried to establish the specific
dementia type in accordance with DSM-5 [19].
Contribution to policy and practice
High permissiveness to prescribe dementia drugs was
related to extensive dementia management by pri-
mary care physicians when compared with low per-
missiveness. This could be of interest for dementia
care stakeholders as a way to incentivize dementia
management [29]. Since studies exploring contempor-
ary dementia management across different countries
from a primary care perspective are rare Unburdening
dementia could be a key for developing policies of
dementia management not limited only to health care
professionals.
To our knowledge, Unburdening presented as a
basic social process [15] has not been published
before for any health issue, let alone for dementia.
Recognising dementia – the first stage of
Unburdening – has indeed been much explored [29]
and the burden concept often appears in qualitative
research on chronic disease management in general
and in dementia care in particular [7,8]. Hence, there
is a vast literature about caregiver burden in dementia
care resulting in emotional distress and burn-out [7].
In a grounded theory dissertation, unburdening was a
subcore concept explaining caregivers coping by
‘telling their stories’ to the researcher [30].
Unburdening by drugs was accompanied by a
broadening of guideline indications for dementia
drugs. This was in some cases mentioned by physi-
cians as motivated by mercy and equity. In a system-
atic review of psychosocial factors of patients’ and
carers’ experiences of dementia diagnosis and treat-
ment, it was found that dementia drugs gave hope
and were considered as ‘worth a try’ although the
benefits were not clear [31]. This view of expectations
should not be neglected in dementia management to
counter therapeutic nihilism [8,29]. Alas, ‘prescription
reflex’ doctoring is especially risky for geriatric patients
[27]. In this study, physicians thus seemed to rely
more on drug treatment to relieve dementia burdens
than what is proposed by today’s updated prescription
guidelines where deprescribing is actually emphasised
in unspecified dementia (but not in Alzheimer’s dis-
ease) [17].
It is almost needless to say that Unburdening by
drugs has general implications for physicians concern-
ing how they deal with many different health issues.
We thus propose that Unburdening by drugs is what
most practicing physicians do every day with or with-
out evidence-based support for the drugs they are
prescribing. So why should it be different for patients
with dementia?
The conceptual framework of Unburdening could be
further developed in order to understand practice
habits for different diseases and hypotheses based on
Unburdening may be tested deductively.
Conclusions
In this grounded theory analysis of an international
primary care physician survey, a basic social process
that we call Unburdening dementia emerged as a reso-
lution for a core concern of the physicians.
Unburdening is suggested as a tentative explanatory
theory of dementia management in primary care start-
ing with Recognising a dementia burden by
Identification and Assessment of dementia followed by
dementia Burden Relief.
Physicians typically identify the burden of both the
patient and family members and then assess the cog-
nitive impairment with MMSE in order to relieve the
dementia burden, commonly by drug prescriptions,
but also by community health and home help services
in unburdening tasks. Dementia drug therapy seemed
inappropriate in 40% of patients where primary care
physicians broadened the guidelines with the purpose
of Unburdening by drugs. Our findings have implica-
tions with regard to how dementia is managed in real
world primary care across many jurisdictions.
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Appendix 1
Exploratory survey on dementia diagnosis and
treatment in your country (jurisdiction)
Country… … … … … … … .… … .
Name: … … … … … … … … … … .
Email:… … … … … …@ … … … … … … … … …
These questions concern the current situation in your own
country or jurisdiction (region or health care district)
Please respond with as many comments as possible since
multiple choice questions do not cover all that is important
in an exploratory study! If you write your e-mail address we
will write you back!
1. Which healthcare professionals are officially responsible
for the diagnosis of dementia?
 Secondary care specialists (neurologist, geriatrician,
psychiatrist, neuropsychiatrist)
2. GPs
3. Both
Comments:… … … … .… … … … … … … … … … …
… … … … … … … … … … … … … … … … … … …
… … … … …
2. Which are the most popular dementia screening tests
used? Please comment if
 MMSE
Clock Drawing Test
Other. Please specify… … … … … … … … … … … … …
… … … … … … … … … … …
Comments:… … … … .… … … … … … … … … … …
… … … … … … … … … … … … … … … … … … …
… … … … …
3. Are GPs allowed to start prescribing drug treatment for
dementia?
 Yes
No
Comments:… … … … .… … … … … … … … … … …
… … … … … … … … … … … … … … … … … … …
… … … … …
4. Is continued dementia drug treatment reimbursed if
prescribed by GPs in your country?
 Yes
No
Comments: … … … … .… … … … … … … … … … …
… … … … … … … … … … … … … … … … … … …
… … … … … … … … … … … … … .
5. Do GPs try to establish a diagnosis of dementia on their
own?
 never
 rarely
 often
 always
Comments: … … … … .… … … … … … … … … … …
… … … … … … … … … … … … … … … … … … …
… … … … … … … … … … …
6. Do GPs refer a suspected case of dementia to a second-
ary care specialist?
 never
rarely
often
always
Comments: … … … … .… … … … … … … … … … …
… … … … … … … … … … … … … … … … … … …
… … … … … … … … … … …
7. What would GPs need to be able to detect dementia
better? More than one response option possible.
 More time in the consultation
Incentives
Easy and short dementia tools
Other… … … … … … … … … … … … … … …
Comments:… … … … .… … … … … … … … … … …
… … … … … … … … … … … … … … … … … … …
… … … … …
8. Please tell as much as possible about a case of demen-
tia in your practice! (or tell us in a later e-mail)
… … … … .… … … … … … … … … … … … … … …
… … … … … … … … … … … … … … … … … … …
… … … … … … …
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Appendix 2
Exclusion criteria for anti-amyloid trials
Anti-amyloid trials
Key Exclusion Criteria:
 Any medical or neurological condition (other than Alzheimer’s
D.) that might be a contributing cause of cognitive
impairment.
 Stroke or Transient Ischaemic Attack (TIA) or unexplained loss
of consciousness in the past year.
 Clinically significant psychiatric illness in past six months.
 Seizure in the past three years.
 Poorly controlled diabetes mellitus.
 Unstable angina, myocardial infarction, chronic heart failure,
or clinical significant conduction abnormalities past year.
 Impaired renal or liver function.
 Human immunodeficiency virus (HIV) infection.
 Significant systematic illness or infection in past 30 days.
 Brain MRI showing acute or sub-acute micro or macrohae-
morrhage, >4 microhaemorrhages, cortical infarct or > 1
lunar infarct.
 Any contraindications to brain MRI or PET scans.
 Negative PET scan with any amyloid-targeting ligand last 48
weeks.
 Clinically significant 12-lead electrocardiogram (ECG)
abnormalities.
 Alcohol or substance abuse in past 1 year.
 Taking blood thinners (except for aspirin at prophylactic dose
or less)
 Changes in medications or doses of medication in past 4
weeks.
Adapted from Sevigny et al, Nature 2016 (The antibody aducanu-
mab reduces Ab plaques in Alzheimer’s disease)
Donepezil
Patients were excluded from the donepezil studies if they had
insulin-dependent diabetes mellitus or other endocrine disorder,
asthma, obstructive pulmonary disease or clinically significant
uncontrolled gastrointestinal hepatic or cardiovascular diseases.
Patients known to be hypersensitive to cholinesterase inhibitors
or who had taken tacrine or other investigational medicines
within one month of baseline were excluded. Concomitant medi-
cations such as anticholinergics, anticonvulsants, antidepressants
and antipsychotics were not allowed. Drugs with central nervous
system (CNS) activity were prohibited or partially restricted.
Galantamine
Some stable and well-controlled concomitant medical disorders
were not reason for exclusion (hypertension, heart failure, diabetes
and hypothyroidism). The list of reasons for exclusion was quite
extensive and consistent across studies, other neurodegenerative
illness, cardiovascular disease, or active cerebrovascular disease,
clinically significant infarct dementia, psychiatric, hepatic, renal,
pulmonary, metabolic, endocrine, active peptic ulcer, history of
epilepsy, drug or alcohol abuse.
Rivastigmine
The list of exclusions was not extensive. Patients with severe and
unstable illnesses (cardiovascular or pulmonary disease, unstable
diabetes mellitus, peptic ulceration within the preceding five
years, evidence of alcohol or substance abuse) were excluded, as
were subjects taking medications such as anticholinergic drugs,
acetyl-choline precursor health food supplements, memory
enhancers, insulin and psychotropic drugs.
FACT BOX
Donepezil studies
Patients were excluded if they had: insulin-dependent diabetes
mellitus, other endocrine disorder, asthma, obstructive pulmonary
disease or clinically significant uncontrolled gastrointestinal hep-
atic or cardiovascular diseases. Medications such as anticholiner-
gics, anticonvulsants, antidepressants and antipsychotics.
Galantamine studies
Patients were excluded if they had: other neurodegenerative ill-
ness, cardiovascular disease, or active cerebrovascular disease,
clinically significant infarct dementia, psychiatric, hepatic, renal,
pulmonary, metabolic, endocrine, active peptic ulcer, history of
epilepsy, drug or alcohol abuse.
Rivastigmine studies
Patients were excluded if they had: severe and unstable illnesses
(cardiovascular or pulmonary disease, unstable diabetes mellitus,
peptic ulceration within five years, alcohol or substance abuse),
medications such as anticholinergic drugs, acetylcholine precursor
health food supplements, memory enhancers, insulin and psycho-
tropic drugs.
Adapted from: AChEI, Cholinesterase inhibitors for Alzheimer’s
disease, Birks J, The Cochrane Library 2009, Issue 1
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. Donepezil
Patients were excluded from the donepezil studies if they had
insulin-dependent diabetes mellitus or other endocrine disorder,
asthma, obstructive pulmonary disease or clinically significant
uncontrolled gastrointestinal hepatic or cardiovascular diseases.
Patients known to be hypersensitive to cholinesterase inhibitors
or who had taken tacrine or other investigational medicines
within one month of baseline were excluded. Concomitant medi-
cations such as anticholinergics, anticonvulsants, antidepressants
and antipsychotics were not allowed. Drugs with central nervous
system (CNS) activity were prohibited or partially restricted.
Appendix 3
Exclusion criteria for dementia drug RCTs
. Galantamine
Some stable and well-controlled concomitant medical disorders
were not reason for exclusion (hypertension, heart failure, dia-
betes and hypothyroidism). The list of reasons for exclusion was
quite extensive and consistent across studies, other neurodege-
nerative illness, cardiovascular disease, or active cerebrovascular
disease, clinically significant infarct dementia, psychiatric, hepatic,
renal, pulmonary, metabolic, endocrine, active peptic ulcer, his-
tory of epilepsy, drug or alcohol abuse.
. Rivastigmine
The list of exclusions was not extensive. Patients with severe and
unstable illnesses (cardiovascular or pulmonary disease, unstable
diabetes mellitus, peptic ulceration within the preceding five
years, evidence of alcohol or substance abuse) were excluded, as
were subjects taking medications such as anticholinergic drugs,
acetyl-choline precursor health food supplements, memory
enhancers, insulin and psychotropic drugs.
. FACT BOX
Donepezil studies
Patients were excluded if they had: insulin-dependent diabetes
mellitus, other endocrine disorder, asthma, obstructive pulmonary
disease or clinically significant uncontrolled gastrointestinal hep-
atic or cardiovascular diseases. Medications such as anticholiner-
gics, anticonvulsants, antidepressants and antipsychotics.
Galantamine studies
Patients were excluded if they had: other neurodegenerative ill-
ness, cardiovascular disease, or active cerebrovascular disease,
clinically significant infarct dementia, psychiatric, hepatic, renal,
pulmonary, metabolic, endocrine, active peptic ulcer, history of
epilepsy, drug or alcohol abuse.
Rivastigmine studies
Patients were excluded if they had: severe and unstable illnesses
(cardiovascular or pulmonary disease, unstable diabetes mellitus,
peptic ulceration within five years, alcohol or substance abuse),
medications such as anticholinergic drugs, acetylcholine precursor
health food supplements, memory enhancers, insulin and psycho-
tropic drugs.
Adapted from: AChEI, Cholinesterase inhibitors for Alzheimer’s dis-
ease, Birks J, The Cochrane Library 2009, Issue 1
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